Thermo Fisher Expands AI and Manufacturing Capabilities at BIO International 2026
Event summary
- Thermo Fisher Scientific showcased new capabilities in AI-enabled research, clinical development, and advanced manufacturing at BIO International 2026.
- Expanded global sterile fill-finish capacity and device assembly collaboration with SHL Medical at Ridgefield, New Jersey site.
- Launched new GMP monoclonal antibody manufacturing capabilities in Plainville, Massachusetts, set to open in the second half of 2026.
- Acquired Clario Holdings Inc. to enhance digital clinical research capabilities, supporting approximately 70% of FDA and EMA novel drug approvals over the past decade.
The big picture
Thermo Fisher's strategic investments at BIO International 2026 underscore the growing demand for advanced therapies and data-driven approaches in drug development. The company's expanded capabilities in AI, manufacturing, and clinical research position it as a key player in simplifying complex workflows and accelerating therapy delivery. With annual revenue over $45 billion, Thermo Fisher is well-positioned to support biopharma companies in translating breakthrough science into commercial success.
What we're watching
- AI Integration
- How Thermo Fisher's AI-enabled workflows will impact the efficiency of drug development processes.
- Manufacturing Scale
- Whether the expanded manufacturing capabilities can meet the increasing demand for biologic therapies.
- Clinical Research Efficiency
- The pace at which AI and real-world evidence solutions will streamline clinical trial operations.